Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
30 mars 2022 07h00 HE
|
Cognition Therapeutics, Inc.
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program -- Conference call and...
ProMIS Neurosciences Announces Fiscal Year 2021 Results
17 mars 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused...
Cognition Therapeutics Announces Participation in March Investment Conferences
08 mars 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX
25 févr. 2022 20h45 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc....
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
24 févr. 2022 16h01 HE
|
Cyclerion Therapeutics, Inc.
Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment...
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
26 janv. 2022 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Lui Franciosi To Assess the Safety and Efficacy of a New Dementia Treatment
05 janv. 2022 16h00 HE
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be reviewing and monitoring the safety and efficacy of the new...
Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering
15 nov. 2021 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
09 nov. 2021 16h01 HE
|
Cyclerion Therapeutics, Inc.
First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment...
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
22 sept. 2021 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function,...